header-aidsvaccine

HIV Orange
AIDS Vaccine Basics is comprised of our popular Primer series, textbook-like chapters of about 800 words each that aim to translate the complex world of AIDS vaccine science into simple but informative language. Here you will find deftly written explanations on how different AIDS vaccine strategies work, what cells comprise the different arms of the human immune system, and how to interpret the results of AIDS vaccine trials. The page contains a searchable key that allows readers to track down Primer topics dating back to 2003.

Understanding Data Safety Monitoring Boards
VAX-5(6)-June-2007
How do DSMBs monitor ongoing clinical trials?
Read More »

Understanding Partially Effective AIDS Vaccines
VAX-5(5)-May-2007
What is a partially effective vaccine and how can it limit the spread of HIV?
Read More »

Understanding the Challenges of AIDS Vaccine Development
VAX-5(4)-April-2007
What are the major scientific obstacles to the development of an effective AIDS vaccine?
Read More »

Understanding Why an Effective AIDS Vaccine is Feasible
VAX-5(3)-March-2007
What evidence exists for immune control of HIV/SIV?
Read More »

Understanding Neutralizing Antibodies
VAX-5(2)-February-2007
Why are HIV-specific neutralizing antibodies so difficult to induce with vaccination?
Read More »

Understanding Immune Correlates of Protection, Part II
VAX-4(12)-December-2006
How can animal models be used to identify the correlates of protection for an AIDS vaccine?
Read More »

Understanding Immune Correlates of Protection, Part I
VAX-4(11)-November-2006
How can researchers identify the correlates of protection for an AIDS vaccine?
Read More »

Understanding AIDS Vaccine Pre-clinical Development
VAX-4(10)-October-2006
How are AIDS vaccine candidates tested for safety and immunogenicity before they enter clinical trials?
Read More »

Understanding Long-term Nonprogressors
VAX-4(9)-September-2006
What can AIDS vaccine researchers learn from studying people who are HIV infected but progress more slowly to AIDS?
Read More »

Understanding HIV Clades
VAX-4(7)-July-2006
How does the genetic diversity of HIV affect AIDS vaccine design?
Read More »

Understanding Home-Based Voluntary Counseling and Testing
VAX-4(6)-June-2006
How can home-based or mobile services for HIV counseling and testing improve community responses?
Read More »

Understanding Referral Networks in AIDS Vaccine Trials
VAX-4(5)-May-2006
What is the process for referring volunteers in vaccine trials for treatment and care?
Read More »

Understanding the Early Stages of HIV Infection
VAX-4(4)-April-2006
How can studying what happens immediately following HIV infection help researchers design an AIDS vaccine?
Read More »

Understanding Capacity Building at Vaccine Trial Sites
VAX-4(3)-March-2006
How can AIDS vaccine trials help build infrastructure and capacity in developing countries?
Read More »

Understanding the Benefits and Risks of Participating in Clinical Research
VAX-4(2)-February-2006
What are the major considerations influencing the decision to volunteer for an AIDS vaccine trial?
Read More »

Understanding Mucosal Immunity
VAX-3(12)-December-2005
How could the need to assess mucosal immunity affect AIDS vaccine trials?
Read More »

Understanding HIV Testing
VAX-3(11)-November-2005
How can participation in an AIDS vaccine trial affect HIV test results?
Read More »

Understanding Couples Voluntary Counseling and Testing
VAX-3(10)-October-2005
Why is voluntary counseling and testing for couples an important process for recruiting women into vaccine trials?
Read More »

Understanding Test-of-Concept Trials
VAX-3(9)-September-2005
Why are Phase IIb trials an important step in evaluating AIDS vaccine candidates?
Read More »

Understanding Risk-Reduction Counseling
VAX-3(8)-August-2005
Why is risk-reduction counseling an important part of AIDS vaccine trials?
Read More »